Rapport’s novel oral drug posts Phase II bipolar win
Rapport Therapeutics’ Phase II bipolar mania study has met its primary endpoint, as it hopes to compete on the market…
News
EyePoint halves workforce and ends Phase III trial early after endpoint miss
Veradermics’ stock up on male hair loss trial success
Lilly’s Omvoh leads to 50% clinical remission rate in paediatric UC
Zentalis reports survival data from azenosertib ovarian cancer study
Cyrano’s Phase II trial of CYR-064 meets primary safety endpoint
First patient dosed in MacroGenics’ Phase I MGC030 trial
Merz concludes enrolment in Phase III Xeomin trials for migraine
